We recently compiled a list of the Jim Cramer Discussed These 10 Stocks, AI Power Demand & Healthcare. In this article, we ...

Apple has been ranked as Fortune's Most Admired Company for the 18th consecutive year. The Fortune rankings are based on a survey of ...

European equity markets are set to open higher on Friday to cap a positive week for stocks. The U.K.'s FTSE 100 is set to ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

The European Commission has granted marketing authorisation for Novo Nordisk’s adult diabetes ... Advisory Committee in November 2012. The JP Morgan Healthcare Conference is seen as a barometer ...

Diabetes specialist Novo Nordisk is feeling the heat from increasingly ... their new AI agent for clinical trial recruitment. The JP Morgan Healthcare Conference is seen as a barometer for the ...

Drugmakers hope to see efforts that focus more on cracking down on pharmacy benefit managers while promoting drug innovation ...

The S&P 500 closed lower after hitting new records on Friday, as investors took some profit to end a solid week centered on President Donald Trump 's return to the White House.

U.S. drugmaker Pfizer PFE.N is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

If there's a group even dumber, unfortunately, it would be foreign retail investors. And they're buying U.S. stocks like they're going out of fashion.

JPMorgan analyst Jessica Fye adjusted the price target for Ascendis Pharma (NASDAQ:ASND), a $7.74 billion biotech company, to $167.00, a slight increase from the previous $165.00, while reiterating ...

LEXX READ THE FULL LEXX RESEARCH REPORT Lexaria Bioscience Corporation (NASDAQ:LEXX) reported fiscal first quarter 2025 ...